SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Nag S, Beyer D, Friedlander J, Grimm P, Nath R. American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys. 1999; 44: 789799.
  • 2
    Davis BJ, Pisansky TM, Wilson TM, et al. The radial distance of extraprostatic extension of prostate carcinoma—Implications for prostate brachytherapy. Cancer. 1999; 85: 26302637.
  • 3
    Davis BJ, Haddock MG, Wilson TM, et al. Treatment of extraprostatic cancer in clinically-confined prostate cancer by permanent interstitial brachytherapy: is extraprostatic seed placement necessary? Tech Urol. 2000; 6: 7077.
  • 4
    Sohayda C, Kupelian PA, Levin HS, Klein EA. Extent of extracapsular extension in localized prostate cancer. Urology. 2000; 55: 382386.
  • 5
    American Joint Committee on Cancer. Manual for staging of cancer. Philadelphia: JB Lippincott, 1992.
  • 6
    Blasko JC, Ragde H, Luse RW, Sylvester JE, Cavanagh W, Grimm PD. Should brachytherapy be considered a therapeutic option in localized prostate cancer? Urol Clin North Am. 1996; 23: 633650.
  • 7
    Baker LH, Bahnson RR, Hanks GE, et al. NCCN practice guidelines for prostate cancer. Oncology. 2000; 14: ( 11A Suppl) 111119.
  • 8
    Pisansky TM, Zincke H, Suman VJ, Bostwick DG, Earle JD, Oesterling JE. Correlation of pretherapy prostate cancer characteristics with histologic findings from pelvic lymphadenectomy specimens. Int J Radiat Oncol Biol Phys. 1996; 34: 3339.
  • 9
    Pisansky TM, Blute ML, Suman VJ, Bostwick DG, Earle JD, Zincke H. Correlation of pretherapy prostate cancer characteristics with seminal vesicle invasion in radical prostatectomy specimens. Int J Radiat Oncol Biol Phys. 1996; 36: 585591.
  • 10
    Partin AW, Kattan MW, Subong EN, et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA. 1997; 277: 14451451.
  • 11
    Morgan WR, Lieber MM. Pelvic lymphadenectomy. In: CrawfordED, DasS, editors. Current genitourinary cancer surgery. Philadelphia: Lea and Febiger, 1990: 162169.
  • 12
    Gleason DF. Histologic grading of prostatic carcinoma. In: BostwickDG, editor. Pathology of the prostate. New York: Churchill Livingstone, 1990: 8393.
  • 13
    Walker SH, Duncan DB. Estimation of the probability of an event as a function of several independent variables. Biometrika. 1967; 54: 167179.
  • 14
    McNeil BJ, Hanley JA. Statistical approaches to the analysis of receiver operating characteristic (ROC) curves. Med Decision Making. 1984; 4: 137150.
  • 15
    Efron B, Tibshirani R. An introduction to the bootstrap. New York: Chapman & Hall, 1993.
  • 16
    Movsas B, Hanlon AL, Teshima T, Hanks GE. Analyzing predictive models following definitive radiotherapy for prostate carcinoma. Cancer. 1997; 80: 10931102.
  • 17
    Prestidge BR, Prete JJ, Buchholz TA, et al. A survey of current clinical practice of permanent prostate brachytherapy in the United States. Int J Radiat Oncol Biol Phys. 1998; 40: 461465.
  • 18
    Critz FA, Williams WH, Holladay CT, et al. Post-treatment PSA ≤ 0.2 ng/mL defines disease freedom after radiotherapy for prostate cancer using modern techniques. Urology. 1999; 54: 968971.
  • 19
    Grado GL, Larson TR, Balch CS, et al. Actuarial disease-free survival after prostate cancer brachytherapy using interactive techniques with biplane ultrasound and fluoroscopic guidance. Int J Radiat Oncol Biol Phys. 1998; 42: 289298.
  • 20
    Potters L, Cha C, Oshinsky G, Venkatraman E, Zelefsky M, Leibel S. Risk profiles to predict PSA relapse-free survival for patients undergoing permanent prostate brachytherapy. Cancer J Sci Am. 1999; 5: 301306.
  • 21
    Blasko JC. Brachytherapy. Urology. 2000; 55: 306308.
  • 22
    Brachman DG, Thomas T, Hilbe J, Beyer DC. Failure-free survival following brachytherapy alone or external beam irradiation alone for T1-2 prostate tumors in 2222 patients: results from a single practice. Int J Radiat Oncol Biol Phys. 2000; 48: 111117.
  • 23
    D'Amico AV, Schnall M, Whittington R, et al. Endorectal coil magnetic resonance imaging identifies locally advanced prostate cancer in select patients with clinically localized disease. Urology. 1998; 51: 449454.
  • 24
    Stock RG, Stone NN, Ianuzzi C, Unger P. Seminal vesicle biopsy and laparoscopic pelvic lymph node dissection. Implications for patient selection in the radiotherapeutic management of prostate cancer. Int J Radiat Oncol Biol Phys. 1995; 33: 815821.
  • 25
    Tindall DJ, Scardino PT. Defeating prostate cancer: crucial directions for research-excerpt from the report of the Prostate Cancer Progress Review Group. Prostate. 1999; 38: 166171.
  • 26
    Stone NN, Stock RG, Unger P. Effects of neoadjuvant hormonal therapy on prostate biopsy results after I-125 and Pd-103 seed implantation. Mol Urol. 2000; 4: 163168.